2022年1月6日至2022年3月21日中国香港特别行政区的新冠病毒病死亡率及疫苗接种率
COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.
作者信息
Smith Dallas J, Hakim Avi J, Leung Gabriel M, Xu Wenbo, Schluter W William, Novak Ryan T, Marston Barbara, Hersh Bradley S
机构信息
CDC COVID-19 Response International Task Force, Atlanta.
Epidemic Intelligence Service, CDC.
出版信息
China CDC Wkly. 2022 Apr 8;4(14):288-292. doi: 10.46234/ccdcw2022.071.
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: COVID-19 vaccines are important tools to protect populations from severe disease and death.
WHAT IS ADDED BY THIS REPORT?: Among persons aged ≥60 years in Hong Kong, 49%, had received ≥2 doses of a COVID-19 vaccine, and vaccination coverage declined with age. During January-March 2022, reported COVID-19-associated deaths rose rapidly in Hong Kong. Among these deaths, 96% occurred in persons aged ≥60 years; within this age group, the risk for death was 20 times lower among those who were fully vaccinated compared with those who were unvaccinated.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: Efforts to identify and address gaps in age-specific vaccination coverage can help prevent high mortality from COVID-19, especially in older adults.
摘要
关于该主题已知的信息有哪些？：新冠疫苗是保护人群免受重症和死亡的重要工具。
本报告新增了哪些内容？：在香港60岁及以上人群中，49%的人接种了≥2剂新冠疫苗，且疫苗接种覆盖率随年龄增长而下降。在2022年1月至3月期间，香港报告的新冠相关死亡人数迅速上升。在这些死亡病例中，96%发生在60岁及以上人群中；在该年龄组内，与未接种疫苗的人相比，完全接种疫苗的人死亡风险低20倍。
对公共卫生实践有何启示？：识别和解决特定年龄组疫苗接种覆盖率差距的努力有助于预防新冠导致的高死亡率，尤其是在老年人中。
相似文献
1
COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.
China CDC Wkly. 2022 Apr 8;4(14):288-292. doi: 10.46234/ccdcw2022.071.
2
COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.
MMWR Morb Mortal Wkly Rep. 2022 Apr 15;71(15):545-548. doi: 10.15585/mmwr.mm7115e1.
3
Association Between COVID-19 Vaccination Coverage and Case Fatality Ratio: a Comparative Study - Hong Kong SAR, China and Singapore, December 2021-March 2022.
China CDC Wkly. 2022 Jul 29;4(30):649-654. doi: 10.46234/ccdcw2022.140.
4
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12.
5
Economic Value of Vaccines to Address the COVID-19 Pandemic in Hong Kong: A Cost-Effectiveness Analysis.
Vaccines (Basel). 2022 Mar 23;10(4):495. doi: 10.3390/vaccines10040495.
6
COVID-19 outbreaks in residential care homes in Hong Kong and effectiveness of vaccine against severe outcomes.
Infect Med (Beijing). 2023 Mar;2(1):1-10. doi: 10.1016/j.imj.2023.01.002. Epub 2023 Jan 14.
7
Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series.
Lancet Healthy Longev. 2022 Jul;3(7):e491-e500. doi: 10.1016/S2666-7568(22)00125-8. Epub 2022 Jul 4.
8
Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases.
J Clin Virol. 2023 Sep;166:105547. doi: 10.1016/j.jcv.2023.105547. Epub 2023 Jul 10.
9
Public health impact of herpes zoster vaccination on older adults in Hong Kong.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2176065. doi: 10.1080/21645515.2023.2176065. Epub 2023 Feb 28.
10
Multilevel Determinants of COVID-19 Vaccine Uptake Among South Asian Ethnic Minorities in Hong Kong: Cross-sectional Web-Based Survey.
JMIR Public Health Surveill. 2021 Nov 9;7(11):e31707. doi: 10.2196/31707.
引用本文的文献
1
Explanatory spatial modeling of COVID-19 vaccine coverage in Thailand: policy implications for equitable distribution.
BMC Public Health. 2025 Sep 2;25(1):3028. doi: 10.1186/s12889-025-24217-7.
2
Real-World Effectiveness of Nirmatrelvir/Ritonavir in Hospitalized Older Adults with Severe Omicron COVID-19: A Retrospective Cohort Study from China.
Infect Drug Resist. 2025 Jun 7;18:2901-2909. doi: 10.2147/IDR.S518205. eCollection 2025.
3
Risk of extended viral shedding of Omicron BA.2 in Shanghai: Implications for vaccination strategy optimization.
Chin Med J Pulm Crit Care Med. 2023 Dec 7;1(4):241-248. doi: 10.1016/j.pccm.2023.11.001. eCollection 2023 Dec.
4
Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study.
EClinicalMedicine. 2024 May 3;72:102620. doi: 10.1016/j.eclinm.2024.102620. eCollection 2024 Jun.
5
Young adults' intention to encourage COVID-19 vaccination among their grandparents: A nationwide cross-sectional survey of college students in China.
Vaccine X. 2024 Jan 17;16:100439. doi: 10.1016/j.jvacx.2024.100439. eCollection 2024 Jan.
6
Vaccine Effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 in CKD.
Clin J Am Soc Nephrol. 2024 Apr 1;19(4):418-428. doi: 10.2215/CJN.0000000000000376. Epub 2023 Dec 26.
7
COVID-19 Epidemiology during Delta Variant Dominance Period in 45 High-Income Countries, 2020-2021.
Emerg Infect Dis. 2023 Sep;29(9):1757-1764. doi: 10.3201/eid2909.230142. Epub 2023 Jul 26.
8
An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.
Nat Commun. 2023 Apr 12;14(1):2081. doi: 10.1038/s41467-023-37697-1.
9
Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2.
Front Public Health. 2023 Jan 12;10:1087800. doi: 10.3389/fpubh.2022.1087800. eCollection 2022.
10
Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection.
J Med Virol. 2023 Feb;95(2):e28497. doi: 10.1002/jmv.28497.
本文引用的文献
1
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
Lancet Infect Dis. 2022 Oct;22(10):1435-1443. doi: 10.1016/S1473-3099(22)00345-0. Epub 2022 Jul 15.
2
Willingness to accept COVID-19 vaccine among the elderly and the chronic disease population in China.
Hum Vaccin Immunother. 2021 Dec 2;17(12):4873-4888. doi: 10.1080/21645515.2021.2009290. Epub 2021 Dec 14.
3
Interpretation of the Protocol for Prevention and Control of COVID-19 in China (Edition 8).
China CDC Wkly. 2021 Jun 18;3(25):527-530. doi: 10.46234/ccdcw2021.138.
4
Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China.
Nat Med. 2020 Apr;26(4):506-510. doi: 10.1038/s41591-020-0822-7. Epub 2020 Mar 19.
Zotero 插件